Updated on 18 December 2015
Australia's AtCor Medical Holdings Limited, the developer and marketer of the SphygmoCor system which measures central aortic blood pressures and arterial stiffness non-invasively, and Japan's A&D Company, have signed a multi-year exclusive distribution contract enabling A&D to distribute AtCor's SphygmoCor XCEL device in Japan.
SphygmoCor XCEL will initially be marketed to researchers as a class one device under the Japanese Ministry of Health's regulations whilst a class 2 submission to allow clinical use is submitted and reviewed. AtCor and A&D expect the Ministry will review the class 2 submission in 2016.
The Japanese Society of Hypertension Guidelines, released in 2014, identified central blood pressure and augmentation index as markers of advanced cardiac disease; and pulse wave velocity as a marker of end organ damage (which is damage occurring in the body's major organs such as the heart, kidneys or brain).
SphygmoCor XCEL provides both measurements, unlike other devices in Japan that only measure one parameter. A&D will promote the SphygmoCor XCEL device through their sales force which is dedicated to selling blood pressure devices to hospitals and doctors in Japan. The A&D sales force has completed training to demonstrate and use SphygmoCor XCEL and marketing in Japan has already commenced, with A&D promoting SphygmoCor XCEL at several local medical exhibitions.